The drug combination was generally well tolerated, with side effects consistent with the known profiles of the individual drugs
In clinical trials, patients treated with GLP-1 injections lost an average of 12.4%17.8% more body weight than the placebo group over the course of a year
As this data is based on a simulation, not a patient-cohort or randomised clinical trial, the authors stressed its limitations
According to FDA prescribing information, these include: Nausea (occurring in 1544% of patients depending on formulation and dose) Vomiting (524% of patients) Diarrhea (830% of patients) Abdominal pain (511% of patients) Constipation (324% of patients) These gastrointestinal symptoms typically emerge during dose escalation and often diminish over time as physiological tolerance develops
Future studies are needed to identify which people with MS are most likely to benefit from taking a GLP-1, the safest dosing strategies, and whether these medications have long-term disease-modifying effects in MS, she says
S.JanelidzeS.MatssonV